Dorene M Rentz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5419830/publications.pdf

Version: 2024-02-01

248 papers 13,297 citations

51 h-index ²⁹³³³
108
g-index

312 all docs

312 docs citations

312 times ranked

12191 citing authors

#	Article	IF	CITATIONS
1	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.4	1,863
2	Tau positron emission tomographic imaging in aging and early <scp>A</scp> lzheimer disease. Annals of Neurology, 2016, 79, 110-119.	2.8	778
3	The characterisation of subjective cognitive decline. Lancet Neurology, The, 2020, 19, 271-278.	4.9	627
4	The A4 Study: Stopping AD Before Symptoms Begin?. Science Translational Medicine, 2014, 6, 228fs13.	5.8	588
5	The Preclinical Alzheimer Cognitive Composite. JAMA Neurology, 2014, 71, 961.	4.5	548
6	Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease. JAMA Neurology, 2019, 76, 915.	4.5	512
7	Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia, 2012, 50, 2880-2886.	0.7	379
8	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	1,2	317
9	Cognition, reserve, and amyloid deposition in normal aging. Annals of Neurology, 2010, 67, 353-364.	2.8	313
10	Synergistic Effect of \hat{I}^2 -Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals. JAMA Neurology, 2014, 71, 1379.	4.5	273
11	Loneliness, depression and cognitive function in older U.S. adults. International Journal of Geriatric Psychiatry, 2017, 32, 564-573.	1.3	269
12	Amyloid and <i>APOE \hat{l}_{μ}4</i> interact to influence short-term decline in preclinical Alzheimer disease. Neurology, 2014, 82, 1760-1767.	1.5	246
13	Amyloid- \hat{l}^2 deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain, 2015, 138, 1023-1035.	3.7	207
14	Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurology, 2019, 76, 542.	4.5	201
15	Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nature Neuroscience, 2018, 21, 424-431.	7.1	198
16	Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia, 2011, 49, 2776-2783.	0.7	191
17	Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. American Journal of Psychiatry, 2018, 175, 530-537.	4.0	175
18	The impact of amyloidâ€beta and tau on prospective cognitive decline in older individuals. Annals of Neurology, 2019, 85, 181-193.	2.8	171

#	Article	IF	CITATIONS
19	Sex, amyloid, and ⟨i⟩APOE⟨ i⟩ ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three wellâ€characterized cohorts. Alzheimer's and Dementia, 2018, 14, 1193-1203.	0.4	169
20	Subjective Cognitive Concerns and Neuropsychiatric Predictors of ProgressionÂto the Early Clinical Stages ofÂAlzheimer Disease. American Journal of Geriatric Psychiatry, 2014, 22, 1642-1651.	0.6	167
21	Interactive Associations of Vascular Risk and \hat{l}^2 -Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals. JAMA Neurology, 2018, 75, 1124.	4.5	165
22	Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. JAMA Psychiatry, 2016, 73, 1230.	6.0	164
23	Cognitive Profile of Amyloid Burden and White Matter Hyperintensities in Cognitively Normal Older Adults. Journal of Neuroscience, 2012, 32, 16233-16242.	1.7	161
24	Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 668-677.	1.8	160
25	Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. Alzheimer's Research and Therapy, 2013, 5, 58.	3.0	146
26	Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia. JAMA Neurology, 2015, 72, 446.	4.5	142
27	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid \hat{l}^2 . Alzheimer's and Dementia, 2017, 13, 1004-1012.	0.4	139
28	Subjective cognitive concerns, amyloid- \hat{l}^2 , and neurodegeneration in clinically normal elderly. Neurology, 2015, 85, 56-62.	1.5	127
29	Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology, 2015, 84, 2153-2160.	1.5	120
30	Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global \hat{I}^2 -Amyloid Burden. JAMA Neurology, 2017, 74, 1455.	4.5	119
31	The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography. Science Translational Medicine, 2021, 13, .	5.8	111
32	Fluorodeoxyglucose metabolism associated with tauâ€amyloid interaction predicts memory decline. Annals of Neurology, 2017, 81, 583-596.	2.8	110
33	Harvard Aging Brain Study: Dataset and accessibility. Neurolmage, 2017, 144, 255-258.	2.1	107
34	In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline. Science Translational Medicine, 2021, 13, eabj2511.	5.8	107
35	Associations of Physical Activity and \hat{I}^2 -Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurology, 2019, 76, 1203.	4.5	97
36	PET staging of amyloidosis using striatum. Alzheimer's and Dementia, 2018, 14, 1281-1292.	0.4	93

#	Article	IF	CITATIONS
37	Sex differences in episodic memory in early midlife: impact of reproductive aging. Menopause, 2017, 24, 400-408.	0.8	92
38	Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2015, 46, 63-73.	1.2	87
39	Regional Cortical Thinning Predicts Worsening Apathy and Hallucinations Across the Alzheimer Disease Spectrum. American Journal of Geriatric Psychiatry, 2014, 22, 1168-1179.	0.6	86
40	Use of IQ-Adjusted Norms to Predict Progressive Cognitive Decline in Highly Intelligent Older Individuals Neuropsychology, 2004, 18, 38-49.	1.0	77
41	Vascular Risk and β â€Amyloid Are Synergistically Associated with Cortical Tau. Annals of Neurology, 2019, 85, 272-279.	2.8	75
42	Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. JAMA Network Open, 2019, 2, e198964.	2.8	72
43	Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. Journal of Alzheimer's Disease, 2017, 59, 975-985.	1.2	70
44	Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease. Neuropsychologia, 2017, 99, 343-349.	0.7	67
45	The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 47, 421-432.	1.2	65
46	Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. NeuroImage: Clinical, 2017, 15, 408-414.	1.4	61
47	Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease Neuropsychology, 2016, 30, 624-630.	1.0	60
48	Subjective cognitive concerns, episodic memory, and the <i>APOE</i> $\hat{l}\mu 4$ allele. Alzheimer's and Dementia, 2014, 10, 752.	0.4	57
49	Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia, 2015, 73, 169-175.	0.7	57
50	Social Engagement and Amyloid-β-Related Cognitive Decline in Cognitively Normal Older Adults. American Journal of Geriatric Psychiatry, 2019, 27, 1247-1256.	0.6	56
51	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimer's and Dementia, 2020, 16, 552-560.	0.4	55
52	Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. Brain Imaging and Behavior, 2017, 11, 383-390.	1.1	54
53	Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiology of Aging, 2019, 78, 178-185.	1.5	54
54	Heterogeneity in Suspected Non–Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. JAMA Neurology, 2016, 73, 1185.	4.5	52

#	Article	IF	CITATIONS
55	Regional Cortical Thinning and Cerebrospinal Biomarkers Predict Worsening Daily Functioning Across the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2014, 41, 719-728.	1.2	51
56	Amyloidâ€associated increases in longitudinal report of subjective cognitive complaints. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 444-449.	1.8	51
57	Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden. Neurology, 2017, 88, 1759-1767.	1.5	50
58	Midlife Eriksonian psychosocial development: Setting the stage for late-life cognitive and emotional health Developmental Psychology, 2016, 52, 496-508.	1.2	46
59	Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology, 2017, 88, 1431-1438.	1.5	46
60	Regional tau pathology and loneliness in cognitively normal older adults. Translational Psychiatry, 2018, 8, 282.	2.4	46
61	Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. Neurology, 2021, 96, e619-e631.	1.5	45
62	Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 46, 727-735.	1.2	44
63	Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. Journal of Alzheimer's Disease, 2016, 53, 1097-1105.	1.2	44
64	Subjective cognitive concerns are associated with objective memory performance in Caucasian but not African-American persons. Age and Ageing, 2017, 46, 988-993.	0.7	44
65	Plasma ILâ€12/IFNâ€Î³ axis predicts cognitive trajectories in cognitively unimpaired older adults. Alzheimer's and Dementia, 2022, 18, 645-653.	0.4	39
66	THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS. journal of prevention of Alzheimer's disease, The, 2016, 3, 1-5.	1.5	39
67	Regional Fluorodeoxyglucose Metabolism and Instrumental Activities of Daily Living across the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2014, 42, 291-300.	1.2	38
68	Web Camera Based Eye Tracking to Assess Visual Memory on a Visual Paired Comparison Task. Frontiers in Neuroscience, 2017, 11, 370.	1.4	38
69	Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults. Neurology, 2021, 96, e1844-e1854.	1.5	38
70	Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease. American Journal of Geriatric Psychiatry, 2017, 25, 683-693.	0.6	37
71	Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology, 2015, 85, 48-55.	1.5	36
72	Neuroimaging markers associated with maintenance of optimal memory performance in late-life. Neuropsychologia, 2017, 100, 164-170.	0.7	35

#	Article	IF	Citations
73	Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1. Journal of Alzheimer's Disease, 2020, 75, 437-450.	1.2	35
74	Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia. Journal of Alzheimer's Disease, 2019, 67, 757-768.	1.2	32
75	Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition. Neurobiology of Aging, 2020, 95, 46-55.	1.5	32
76	Lower novelty-related locus coeruleus function is associated with $A\hat{l}^2$ -related cognitive decline in clinically healthy individuals. Nature Communications, 2022, 13, 1571.	5.8	32
77	Association of Social Support With Brain Volume and Cognition. JAMA Network Open, 2021, 4, e2121122.	2.8	31
78	Device-Embedded Cameras for Eye Tracking–Based Cognitive Assessment: Validation With Paper-Pencil and Computerized Cognitive Composites. Journal of Medical Internet Research, 2018, 20, e11143.	2.1	31
79	Concordance between Subjective and Objective Memory Impairment in Volunteer Subjects. Journal of Alzheimer's Disease, 2015, 48, 1109-1117.	1.2	30
80	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. Journal of the International Neuropsychological Society, 2021, 27, 426-438.	1.2	30
81	Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altropane positron emission tomography study. Alzheimer's Research and Therapy, 2014, 6, 52.	3.0	29
82	The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline. Scientific Reports, 2018, 8, 3828.	1.6	28
83	Dynamic change of cognitive reserve: associations with changes in brain, cognition, and diagnosis. Neurobiology of Aging, 2019, 83, 95-104.	1.5	28
84	Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Molecular Psychiatry, 2020, 25, 2599-2607.	4.1	28
85	Associations of Widowhood and \hat{l}^2 -Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults. JAMA Network Open, 2020, 3, e200121.	2.8	27
86	Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. Neurobiology of Aging, 2020, 93, 124-130.	1.5	27
87	Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 14.	3.0	26
88	A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 25.	3.0	24
89	The Impact of Awareness of and Concern About Memory Performance on the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease Dementia. American Journal of Geriatric Psychiatry, 2018, 26, 896-904.	0.6	23
90	Validation of the Spanish Version of the Face Name Associative Memory Exam (S-FNAME) in Cognitively Normal Older Individuals. Archives of Clinical Neuropsychology, 2015, 30, 712-720.	0.3	22

#	Article	IF	Citations
91	Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 99.	3.0	22
92	The impact of COVID-19 on the well-being and cognition of older adults living in the United States and Latin America. EClinicalMedicine, 2021, 35, 100848.	3.2	22
93	Racial and socioeconomic status differences in stress, posttraumatic growth, and mental health in an older adult cohort during the COVID-19 pandemic. EClinicalMedicine, 2022, 45, 101343.	3.2	21
94	Association of Emerging \hat{l}^2 -Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults. Neurology, 2022, 98, .	1.5	20
95	Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 800126.	1.7	19
96	Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. Journal of Alzheimer's Disease, 2020, 75, 1437-1446.	1.2	18
97	Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. Neurology, 2021, 96, .	1.5	18
98	The influence of demographic factors on subjective cognitive concerns and beta-amyloid. International Psychogeriatrics, 2017, 29, 645-652.	0.6	17
99	Building clinically relevant outcomes across the Alzheimer's disease spectrum. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12181.	1.8	16
100	Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Samp; Alzheimer's Symposium. Alzheimer's and Dementia, 2022, 18, 1677-1686.	0.4	16
101	Intelligence quotient–adjusted memory impairment is associated with abnormal single photon emission computed tomography perfusion. Journal of the International Neuropsychological Society, 2007, 13, 821-31.	1.2	14
102	Age-Related Increases in Tip-of-the-tongue are Distinct from Decreases in Remembering Names: A Functional MRI Study. Cerebral Cortex, 2017, 27, 4339-4349.	1.6	14
103	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2020, 12, 138.	3.0	14
104	The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease. journal of prevention of Alzheimer's disease, The, 2015, 2, 242-253.	1.5	14
105	Validation of the Latin American Spanish version of the face-name associative memory exam in a Colombian Sample. Clinical Neuropsychologist, 2020, 34, 1-12.	1.5	13
106	The presubiculum links incipient amyloid and tau pathology to memory function in older persons. Neurology, 2020, 94, e1916-e1928.	1.5	13
107	Mindfulness Training Improves Cognition and Strengthens Intrinsic Connectivity Between the Hippocampus and Posteromedial Cortex in Healthy Older Adults. Frontiers in Aging Neuroscience, 2021, 13, 702796.	1.7	13
108	Disruption of the Ventral Visual Stream in a Case of Reduplicative Paramnesia. Annals of the New York Academy of Sciences, 2000, 911, 447-452.	1.8	12

#	Article	IF	CITATIONS
109	Anticholinergic Amnesia is Mediated by Alterations in Human Network Connectivity Architecture. Cerebral Cortex, 2019, 29, 3445-3456.	1.6	12
110	Impact of BDNF and sex on maintaining intact memory function in early midlife. Neurobiology of Aging, 2020, 88, 137-149.	1.5	12
111	Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring. Neurobiology of Aging, 2016, 40, 61-67.	1.5	11
112	The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 121-129.	1.2	11
113	Observation of Patient and Caregiver Burden Associated with Early Alzheimer's Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study1. Journal of Alzheimer's Disease, 2019, 72, 279-292.	1.2	11
114	Device-Embedded Cameras for Eye Tracking-Based Cognitive Assessment: Implications for Teleneuropsychology. Telemedicine Journal and E-Health, 2020, 26, 477-481.	1.6	10
115	Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI. Neurology, 2022, 98, .	1.5	10
116	IQ-Based Norms for Highly Intelligent Adults. Clinical Neuropsychologist, 2006, 20, 637-648.	1.5	9
117	A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 107-115.	1.2	9
118	Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments. Alzheimer's Research and Therapy, 2019, 11, 4.	3.0	9
119	ARMADA: Assessing reliable measurement in Alzheimer's disease and cognitive aging project methods. Alzheimer's and Dementia, 2022, 18, 1449-1460.	0.4	9
120	Multiple markers contribute to risk of progression from normal to mild cognitive impairment. NeuroImage: Clinical, 2020, 28, 102400.	1.4	8
121	Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly. journal of prevention of Alzheimer's disease, The, 2017, 4, 81-86.	1.5	8
122	Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort. Alzheimer's Research and Therapy, 2022, 14, 43.	3.0	8
123	Association of \hat{l}^2 -Amyloid and Vascular Risk on Longitudinal Patterns of Brain Atrophy. Neurology, 2022, 99, .	1.5	8
124	Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults. NeuroImage: Clinical, 2019, 24, 102097.	1.4	7
125	Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 330-332.	0.9	7
126	The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 104.	3.0	7

#	Article	IF	CITATIONS
127	Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. Neurology, 2020, 95, e1312-e1321.	1.5	7
128	Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer's Disease Biomarkers and Mood Symptoms. Frontiers in Aging Neuroscience, 2021, 13, 806432.	1.7	7
129	Validating Use of Technology for Cognitive Test Assessment. EBioMedicine, 2016, 11, 23-24.	2.7	5
130	An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. Journal of Alzheimer's Disease, 2019, 68, 1161-1170.	1.2	5
131	Neuroimaging correlates of Stages of Objective Memory Impairment (SOMI) system. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12224.	1.2	5
132	Demonstration of Clinical Meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes. Journal of Alzheimer's Disease, 2022, 88, 577-588.	1.2	4
133	Commentary on Composite cognitive and functional measures for early stage Alzheimer's disease trials. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12012.	1.2	2
134	Hypoconnectivity between locus coeruleus and medial temporal lobe during novelty predicts accelerated Aβâ€related cognitive decline. Alzheimer's and Dementia, 2020, 16, e041323.	0.4	2
135	Harmonizing the preclinical Alzheimer cognitive composite for multiâ€cohort studies. Alzheimer's and Dementia, 2020, 16, e047423.	0.4	2
136	Clinical meaningfulness addressed at Alzheimer's Association Research Roundtable. Alzheimer's and Dementia, 2020, 16, 814-814.	0.4	2
137	P1-180: A NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING INSTRUMENT FOR EARLY ALZHEIMER'S DISEASE. , 2014, 10, P365-P365.		1
138	IC-P-087: DETECTING COGNITIVE PROFILES IN THE BIOMARKER STAGES OF PRECLINICAL AD. , 2014, 10, P49-P50		1
139	IC-P-117: AMYLOID-B DEPOSITION IN MILD COGNITIVE IMPAIRMENT IS ASSOCIATED WITH HIPPOCAMPAL HYPERACTIVATION, ATROPHY, AND CLINICAL PROGRESSION. , 2014, 10, P65-P66.		1
140	F4-01-04: TAU PET USING F18-T807: INITIAL EXPERIENCE IN NORMAL ELDERLY AND AD DEMENTIA. , 2014, 10, P242-P242.		1
141	P2-246: GREATER SUBJECTIVE COGNITIVE CONCERNS CORRESPOND WITH ADVANCING STAGES OF PRECLINICAL AD. , 2014, 10, P566-P566.		1
142	O4-01-01: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P265-P265.		1
143	IC-P-068: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden. , 2015, 11, P51-P51.		1
144	F5-05-02: The Harvard Automated Phone Task (APT): A Novel Performance-Based ADL Instrument for Early Alzheimer's Disease. , 2016, 12, P373-P373.		1

#	Article	IF	CITATIONS
145	O5â€07â€04: Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease (AD): 18â€Month Results from the Geras Observational Study. Alzheimer's and Dementia, 2016, 12, P394.	0.4	1
146	ICâ€Pâ€013: Pet Staging of Amyloidosis: Evidence that Amyloid Occurs First in Neocortex and Later in Striatum. Alzheimer's and Dementia, 2016, 12, P20.	0.4	1
147	IC-P-043: Neuroimaging Correlates of Anosognosia in Mild Cognitive Impairment. , 2016, 12, P36-P37.		1
148	O4â€06â€06: The Impact of Anosognosia and Anosodiaphoria on the Prediction of Progression from Mild Cognitive Impairment to Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P346.	0.4	1
149	P4-354: Subjective Cognitive Concerns are Associated with Objective Memory Performance in Older Caucasian but not African-American Persons., 2016, 12, P1173-P1173.		1
150	[P3 \hat{a} €"376]: QRISK2 AND FRAMINGHAM CARDIOVASCULAR RISK SCORES SIGNIFICANTLY CORRELATE WITH IMAGING BIOMARKERS OF PRECLINICAL AD: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P1103.	0.4	1
151	[ICâ€02–03]: TAU AND HIPPOCAMPAL VOLUME REFLECT DISTINCT PROCESSES IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P5.	0.4	1
152	[P4–534]: LINKING MEASURES OF SUBJECTIVE COGNITION ACROSS INTERNATIONAL AGING STUDIES USING ITEM RESPONSE THEORY. Alzheimer's and Dementia, 2017, 13, P1554.	0.4	1
153	O1â€08â€03: DIGITIZED CLOCK DRAWING (DCTCLOCK TM) PERFORMANCE AND ITS RELATIONSHIP AMYLOID AND TAU PET IMAGING MARKERS IN UNIMPAIRED OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P236.	TO 0.4	1
154	ICâ€Pâ€147: QUANTIFYING STAGES OF SUBTLE MEMORY IMPAIRMENT IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P125.	0.4	1
155	Repeated memoryâ€based assessments: Implications for clinical trials and practice. Alzheimer's and Dementia, 2020, 16, e038143.	0.4	1
156	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2020, 16, e044787.	0.4	1
157	Dementia knowledge and associated demographic factors within a registry sample. Alzheimer's and Dementia, 2020, 16, e046177.	0.4	1
158	Extraneous neuroimaging factors do not contribute to sex differences in flortaucipir signal: Analysis of skull binding and partial volume effects. Alzheimer's and Dementia, 2021, 17, .	0.4	1
159	Associations between remote cognitive testing on an individual's own digital device and amyloid burden on neuroimaging in clinically normal older adults: Results from Boston Remote Assessment for Neurocognitive Health (BRANCH). Alzheimer's and Dementia, 2021, 17, .	0.4	1
160	The impact of COVIDâ€19 on the wellâ€being and cognition of older adults living in the United States and Latin America. Alzheimer's and Dementia, 2021, 17, .	0.4	1
161	P3-266: NEUROPSYCHIATRIC SYMPTOMS AND FUNCTIONAL CONNECTIVITY IN MILD COGNITIVE IMPAIRMENT AND COGNITIVELY NORMAL ELDERLY. , 2014, 10, P729-P729.		O
162	O3-07-02: WHITE MATTER BURDEN IN CLINICALLY NORMAL OLDER ADULTS MEDIATES THE RELATIONSHIP BETWEEN AMYLOID BURDEN AND MEMORY FREE RECALL BUT NOT CUED RECALL. , 2014, 10, P221-P222.		0

#	Article	IF	Citations
163	DT-01-02: TEMPORAL NEOCORTICAL TAU DEPOSITION MEASURED WITH PET IS ASSOCIATED WITH LONGITUDINAL DECLINE IN MEMORY PERFORMANCE AMONG CLINICALLY NORMAL ELDERLY. , 2014, 10, P280-P280.		0
164	P2-154: SUBSYNDROMAL DEPRESSION AND ALZHEIMER'S DISEASE BIOMARKERS IN COGNITIVELY NORMAL ELDERLY. , 2014, 10, P527-P528.		0
165	IC-P-152: OLFACTORY IDENTIFICATION AND ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY NORMAL ELDERLY. , 2014, 10, P87-P87.		O
166	O3-10-06: AMYLOID- \hat{l}^2 DEPOSITION IN MILD COGNITIVE IMPAIRMENT IS ASSOCIATED WITH HIPPOCAMPAL HYPERACTIVATION, ATROPHY, AND CLINICAL PROGRESSION. , 2014, 10, P230-P230.		0
167	P1-301: OLFACTORY IDENTIFICATION AND ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY NORMAL ELDERLY., 2014, 10, P422-P422.		O
168	IC-02-01: GREATER SUBJECTIVE COGNITIVE CONCERNS CORRESPOND WITH ADVANCING STAGES OF PRECLINICAL AD. , 2014, 10, P4-P4.		0
169	O4-12-04: DETECTING COGNITIVE PROFILES IN THE BIOMARKER STAGES OF PRECLINICAL AD. , 2014, 10, P276-P276.		O
170	IC-P-084: Neurobiological correlates of anosognosia in mild cognitive impairment: A multimodal investigation using FDG-PET, PiB-PET, and volumetric MRI., 2015, 11, P60-P60.		0
171	P3-217: Moderate caffeine consumption is associated with better memory scores in clinically normal older adults., 2015, 11, P715-P716.		O
172	IC-P-071: Instrumental activities of daily living and functional connectivity in mild cognitive impairment., 2015, 11, P53-P53.		0
173	IC-P-085: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P60-P61.		O
174	P3-162: Instrumental activities of daily living and functional connectivity in mild cognitive impairment. , 2015, 11, P690-P691.		0
175	F3-02-02: Snap in cognitively normal adults. , 2015, 11, P213-P213.		0
176	P2-141: Neurobiological correlates of anosognosia in mild cognitive impairment: A multi-modal investigation using FDG-PET, PiB-PET, and volumetric MRI., 2015, 11, P540-P540.		0
177	P3-135: Clinical and neuroimaging predictors of psychological well-being as measured by the purpose in life scale in cognitively normal older individuals. , 2015, 11, P675-P676.		0
178	IC-P-153: Clinical and neuroimaging predictors of psychological well-being as measured by the purpose in life scale in cognitively normal older individuals., 2015, 11, P102-P103.		0
179	O2-02-03: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden. , 2015, 11, P175-P175.		O
180	O2-02-05: Differential declines in letter versus category fluency over 4 years in biomarker-defined preclinical Alzheimer's disease., 2015, 11, P176-P177.		0

#	Article	lF	CITATIONS
181	O2-11-06: Reciprocal relations of loneliness and cognitive function in older u.s. adults. , 2015, 11, P201-P202.		0
182	P3â€309: Profiles of Cognitive Decline Associated with Biomarkerâ€Defined Preclinical Stages of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P960.	0.4	0
183	P4-217: Regional Fluorodeoxyglucose Hypometabolism is Associated With Greater Apathy Over Time in Early Alzheimer's Disease. , 2016, 12, P1111-P1111.		O
184	ICâ€Pâ€053: Regional Fluorodeoxyglucose Hypometabolism is Associated with Greater Apathy Over Time in Early Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P43.	0.4	0
185	P2-341: Subjective Cognitive Decline Predicts Longitudinal Decline in those with Both Amyloidosis and Neurodegeneration., 2016, 12, P773-P774.		O
186	P3-322: Optimal Memory Performance in Older Adults is Associated with Differences in Hippocampal Volume and Amyloid Status at Baseline and Over 3 Years., 2016, 12, P969-P969.		0
187	ICâ€Pâ€185: The Effect of Tractâ€Specific Loss of White Matter Connectivity on Cognitive Decline in Healthy Older Individuals Depends on Entorhinal T807 Binding. Alzheimer's and Dementia, 2016, 12, P135.	0.4	O
188	F1â€04â€01: Longitudinal Peformance on the Preclinical Alzheimer's Cognitive Composite (PACC) in Subjects with Biomarkerâ€Defined Preclincal ad. Alzheimer's and Dementia, 2016, 12, P167.	0.4	0
189	O1â€13â€01: Anxiety, Social Activity and Amyloid in Cognitively Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P208.	0.4	O
190	O3â€08â€03: The Effect of Tractâ€Specific Loss of White Matter Connectivity on Cognitive Decline in Healthy Older Individuals Depends on Entorhinal T807 Binding. Alzheimer's and Dementia, 2016, 12, P304.	0.4	0
191	O3â€09â€03: Associations between Amyloidosis and Longitudinal Cognitive Decline in Clinically Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P308.	0.4	0
192	O4â€01â€06: Ab+ Clinically Normal Participants with Elevated Tau Show Greatest Decline in the Preclinical Alzheimer's Disease Cognitive Composite. Alzheimer's and Dementia, 2016, 12, P333.	0.4	0
193	O4-06-04: Neuroimaging Correlates of Anosognosia in Mild Cognitive Impairment. , 2016, 12, P345-P346.		0
194	O4â€07â€05: Pet Staging of Amyloidosis: Evidence that Amyloid Occurs First in Neocortex and Later in Striatum. Alzheimer's and Dementia, 2016, 12, P349.	0.4	0
195	P4-325: TAU BURDEN is Associated with Subjective Cognitive Concerns in the Context of \hat{I}^2 -Amyloid Burden in Preclinical ad. , 2016, 12, P1158-P1159.		O
196	War and remembrance: Combat exposure in young adulthood and memory function sixty years later. Comprehensive Psychiatry, 2017, 72, 97-105.	1.5	0
197	[P4–228]: LONGITUDINAL TAU ACCUMULATION IS ASSOCIATED WITH COGNITIVE DECLINE IN NORMAL ELDERLY. Alzheimer's and Dementia, 2017, 13, P1357.	0.4	O
198	[ICâ€Pâ€108]: ASSOCIATIONS BETWEEN MEASURES OF MEDIAL TEMPORAL LOBE NEURODEGENERATION AND ANOSOGNOSIA FOR MEMORY DEFICITS. Alzheimer's and Dementia, 2017, 13, P85.	0.4	0

#	Article	IF	CITATIONS
199	[P1â€"256]: BASELINE CARDIOVASCULAR RISK AND AMYLOID BURDEN SYNERGISTICALLY PREDICT LONGITUDINAL COGNITIVE DECLINE IN CLINICALLY NORMAL ELDERLY: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P347.	0.4	O
200	[P2â€"298]: ASSOCIATIONS BETWEEN MEASURES OF MEDIAL TEMPORAL LOBE NEURODEGENERATION AND ANOSOGNOSIA FOR MEMORY DEFICITS. Alzheimer's and Dementia, 2017, 13, P730.	0.4	0
201	[F1–03–02]: SUBJECTIVE COGNITIVE DECLINE, LONGITUDINAL COGNITIVE PERFORMANCE, AND IMAGING BIOMARKERS IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P176.	0.4	O
202	[O1–13–01]: SUBJECTIVE CONCERNS PREFERENTIALLY ASSOCIATE WITH AMYLOID BURDEN AND MEMORY I CAUCASIANS, BUT WHITE MATTER HYPERINTENSITIES AND EXECUTIVE FUNCTION IN AFRICANâ€AMERICANS. Alzheimer's and Dementia, 2017, 13, P225.	N 0.4	0
203	[O2–10–03]: SEVERITY OF SUBJECTIVE COGNITIVE DECLINE ALIGNS WITH REGIONAL AMYLOID SEVERITY: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P577.	0.4	O
204	[O2–11–04]: COGNITIVE RESERVE RELATES TO GREATER FUNCTIONAL CONNECTIVITY AND STRONGER INTERCONNECTIVITY WITHIN AND BETWEEN NODES, INDEPENDENT OF βâ€AMYLOID: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P582.	0.4	0
205	[F3–05–03]: OBJECTIVE AND SUBJECTIVE COGNITIVE DECLINE IN BLACK AMERICANS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P885.	0.4	O
206	[O3–06–02]: SEMANTIC MEMORY AND PET AMYLOID AND TAU DEPOSITION IN PRECLINICAL AND PRODROMAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P911.	0.4	0
207	[O3–07–06]: THE RELATIONSHIP BETWEEN RECALL OF RECENTLY VERSUS REMOTELY ENCODED FAMOUS FACES AND AMYLOID AND TAU BURDEN IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P917.	0.4	O
208	O3â€12â€01: DECREASED METAâ€MEMORY FOR EPISODIC BUT NOT SEMANTIC INFORMATION IS ASSOCIATED VEARLY TAUOPATHY IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1050.	NITH 0.4	0
209	P1â€327: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITIVE DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P417.	0.4	O
210	O5â€07â€01: BASELINE FINDINGS FROM GERASâ€US: A LONGITUDINAL COHORT STUDY OF RESOURCE USE AND COSTS OF MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER'S DISEASE (AD) IN THE UNITED STATES. Alzheimer's and Dementia, 2018, 14, P1660.) 0.4	0
211	P1â€310: PATTERNS OF CHANGE IN DEPENDENCE LEVELS FOR COMMUNITYâ€DWELLING ALZHEIMER'S PATIENTS 36â€MONTH RESULTS FROM THE GERAS OBSERVATIONAL STUDY. Alzheimer's and Dementia, 2018, 14, P409.	5: 0.4	O
212	O3â€04â€03: AMYLOID IS ASSOCIATED WITH GREATER TAU BURDEN IN CLINICALLY NORMAL FEMALES RELATIVE MALES: FINDINGS FROM TWO INDEPENDENT COHORTS. Alzheimer's and Dementia, 2018, 14, P1019.	7.2	0
213	ICâ€Pâ€159: BRAIN RESILIENCE PROTECTS AGAINST COGNITIVE DECLINE ASSOCIATED WITH ELEVATED AMYLOID BURDEN. Alzheimer's and Dementia, 2018, 14, P134.	0.4	O
214	F4â€08â€02: AMYLOID BURDEN AND VASCULAR RISK ARE INDEPENDENTLY ASSOCIATED WITH SUBJECTIVE COGNITIVE DECLINE IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1394.	0.4	0
215	O1â€10â€03: SEX AND <i>APOE</i> GENOTYPE INFLUENCE THE ASSOCIATION BETWEEN AMYLOID AND LONGITUDINAL TAU PATHOLOGY IN CLINICALLY NORMAL OLDER ADULTS: FINDINGS FROM THE ADNI STUDY. Alzheimer's and Dementia, 2018, 14, P243.	0.4	O
216	ICâ€Pâ€139: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITI DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P116.	VE 0.4	0

#	Article	IF	CITATIONS
217	O2â€08â€06: AMYLOIDâ€Î², COGNITION AND SOCIAL ACTIVITY IN COGNITIVELY NORMAL OLDER ADULTS. Alzhei and Dementia, 2018, 14, P640.	mer's	0
218	0300 Linking Sleep Disturbances with Amyloid and Tau Imaging. Preliminary Findings from the Harvard Aging Brain Study. Sleep, 2019, 42, A122-A123.	0.6	0
219	P4â€607: FREE AND CUED MEMORY IS DISTINCTLY RELATED TO PATHOLOGY IN PRECLINICAL AUTOSOMALâ€DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1557.	0.4	0
220	ICâ€Pâ€037: GERIATRIC DEPRESSION SCALE ITEMâ€LEVEL ANALYSIS IN RELATION TOÂ <i>IN VIVO</i> CORTICAL AMYLOID AND CEREBRAL REGIONAL TAU IN CLINICALLY NORMAL OLDER ADULTS: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2019, 15, P43.	0.4	0
221	ICâ€Pâ€089: ASSOCIATIONS OF REGIONAL CORTICAL THINNING AND LONGITUDINAL COGNITIVE PERFORMANCE THE CONTEXT OF AMYLOID IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2019, 15, P79.	IN 0.4	0
222	F2â€03â€01: CLINICAL MEANINGFULNESS OF SHORTâ€TERM COGNITIVE DECLINE ON THE PRECLINICAL ALZHEIN COGNITIVE COMPOSITEâ€5 (PACCâ€5) IN NORMAL OLDER ADULTS WITH ELEVATED βâ€AMYLOID. Alzheimer's a Dementia, 2019, 15, P518.		0
223	O3â€09â€01: PROTECTIVE EFFECT OF PHYSICAL ACTIVITY ON LONGITUDINAL COGNITIVE DECLINE AND NEURODEGENERATION IN CLINICALLY NORMAL OLDER ADULTS WITH ELEVATED βâ€AMYLOID BURDEN. Alzheimer's and Dementia, 2019, 15, P903.	0.4	0
224	Tracking the origin of tau spread in the brain. Alzheimer's and Dementia, 2020, 16, e037501.	0.4	0
225	Disease progression and costs at twoâ€year followâ€up of GERASâ€US: A threeâ€year study of mild cognitive impairment and mild dementia due to Alzheimer's disease in the United States. Alzheimer's and Dementia, 2020, 16, e038768.	0.4	O
226	Association of tau tangle burden with depressive symptoms in communityâ€dwelling older adults: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e038867.	0.4	0
227	Sex, tau, and cortical thinning in the temporal lobe: Findings from the Harvard Aging Brain Study. Alzheimer's and Dementia, 2020, 16, e040031.	0.4	0
228	The dynamic interplay between longitudinal subjective and objective cognitive decline along the early AD spectrum in the Harvard Aging Brain Study. Alzheimer's and Dementia, 2020, 16, e040260.	0.4	0
229	Evaluating preâ€screening tools for older Latino recruitment into preclinical Alzheimer's disease studies. Alzheimer's and Dementia, 2020, 16, e041571.	0.4	0
230	Estimating an individual's placement on a theoretical continuum using longitudinal cognitive trajectories: Relationships with longitudinal amyloid and Tauâ€PET. Alzheimer's and Dementia, 2020, 16, e043566.	0.4	0
231	Faster rates of tau accumulation in FTPâ€PET in females relative to males, and a crossâ€sectional influence on faster cognitive decline: Preliminary findings from HABS and ADNI. Alzheimer's and Dementia, 2020, 16, e043620.	0.4	0
232	Are amyloid and tau synergistic? How to interpret an amyloid/tau interaction on cognitive decline in clinically normal adults. Alzheimer's and Dementia, 2020, 16, e044310.	0.4	0
233	GAP rater certification program transforms the rater certification process. Alzheimer's and Dementia, 2020, 16, e044936.	0.4	O
234	Plasma ILâ€12/IFNâ€Î³ axis predicts cognitive trajectories in cognitively normal older adults. Alzheimer's and Dementia, 2020, 16, e045497.	0.4	0

#	Article	IF	Citations
235	Distinct contributions of longitudinal tau and amyloid to decline in various cognitive domains in preclinical AD. Alzheimer's and Dementia, 2020, 16, e046075.	0.4	0
236	Surfaceâ€based amyloid and tau correlates of digital clock drawing performance. Alzheimer's and Dementia, 2020, 16, e046461.	0.4	0
237	Association of tau tangle burden with depressive symptoms in communityâ€dwelling older adults: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e046549.	0.4	0
238	Longitudinal increase in depressive symptoms in relation to neurodegeneration in clinically normal older adults: Findings from the Harvard Aging Brain Study. Alzheimer's and Dementia, 2020, 16, e047321.	0.4	0
239	Associations between biomarker status (amyloid, tau) and risk for progression to MCI/Dementia in the Harvard Aging Brain Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
240	Locus coeruleus integrity as a proxy of initial tau burden: in vivo versus ex vivo observations. Alzheimer's and Dementia, 2021, 17, .	0.4	0
241	Sequential early cognitive changes sensitive to rising betaâ€amyloid and tau pathology in preclinical AD. Alzheimer's and Dementia, 2021, 17, .	0.4	0
242	Selfâ€reported history of estrogen hormone therapy differentiates rates of amyloid accumulation (PiBâ€PET) relative to males: Findings from the Harvard Aging Brain Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
243	Disease progression and costs at 3â€year followâ€up of GERASâ€US: A 3â€year study of mild cognitive impairment and mild dementia due to Alzheimer's disease in the United States. Alzheimer's and Dementia, 2021, 17, .	0.4	0
244	The combined influence of betaâ€amyloid and vascular risk on prospective brain atrophy in clinically normal individuals. Alzheimer's and Dementia, 2021, 17, .	0.4	0
245	Longitudinal trajectories of remote assessment of self―and study partner―ated cognitive concerns, mood and Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	0
246	Monthly computerized atâ€home assessments to detect cognitive change in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
247	Association between the Harvard automated phone task and Alzheimerâ \in ^M s disease pathology in clinically normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
248	Multimodal neuroimaging biomarkers of Alzheimer's disease in older adults with depression: Preliminary findings from a pilot cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	0